C WorldWide Group Holding A S Sells 5,044 Shares of Celgene Co. (CELG)

C WorldWide Group Holding A S lowered its stake in Celgene Co. (NASDAQ:CELG) by 2.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 179,019 shares of the biopharmaceutical company’s stock after selling 5,044 shares during the quarter. Celgene accounts for 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 27th largest position. C WorldWide Group Holding A S’s holdings in Celgene were worth $26,105,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Flagship Harbor Advisors LLC boosted its stake in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new position in shares of Celgene during the 1st quarter worth $385,000. Horizon Investment Services LLC purchased a new position in shares of Celgene during the 1st quarter worth $3,207,000. Bank of Nova Scotia raised its position in shares of Celgene by 340.0% during the 1st quarter. Bank of Nova Scotia now owns 192,020 shares of the biopharmaceutical company’s stock valued at $23,893,000 after purchasing an additional 148,375 shares during the period. Finally, North Star Asset Management Inc. bought a new stake in shares of Celgene during the 1st quarter valued at $201,000. Institutional investors own 79.71% of the company’s stock.

Several analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research report on Wednesday. Cantor Fitzgerald restated a “hold” rating and set a $112.00 price objective on shares of Celgene in a research report on Monday. SunTrust Banks restated a “buy” rating and set a $139.00 price objective (up from $127.00) on shares of Celgene in a research report on Friday, January 26th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective on the stock in a research report on Thursday, January 25th. Finally, BMO Capital Markets restated a “buy” rating and set a $144.00 price objective on shares of Celgene in a research report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Celgene has a consensus rating of “Buy” and a consensus price target of $130.35.

Celgene Co. (NASDAQ CELG) traded down $0.82 during mid-day trading on Thursday, hitting $100.34. 7,290,648 shares of the company were exchanged, compared to its average volume of 7,510,000. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The stock has a market cap of $79,000.00, a PE ratio of 27.80, a PEG ratio of 0.72 and a beta of 1.77.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 64.14%. The firm had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same period in the previous year, the company earned $1.61 EPS. The firm’s revenue for the quarter was up 16.9% compared to the same quarter last year. equities research analysts predict that Celgene Co. will post 7.66 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/02/c-worldwide-group-holding-a-s-has-26-11-million-holdings-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply